Art. -Nr.: HY-163719

PARP7-IN-22

Kundenbewertung

Based on 1 Customer Validation

PARP7-IN-22 (XLY-1) is a PARP7 inhibitor with an IC₅₀ of 0.6 nM. PARP7-IN-22 (XLY-1) is orally active, enhances type I interferon signaling in vitro, restores type I interferon signaling, promotes T cell infiltration into tumor tissues, and significantly inhibits tumor growth. PARP7-IN-22 shows promise for research in the field of cancer immunotherapy.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.59%
CAS. Nr.: 2946705-91-3
Formel: C₁₉H₂₂F₆N₈O₂
Molecular Weight:508.42

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

PARP7-IN-22 Chemical Structure

CAS. Nr.: 2946705-91-3

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target^[1]

PARP-7

0.6 nM (IC₅₀)

Alle PARP Isoform-spezifische Produkte anzeigen :

In Vitro

PARP7-IN-22 (XLY-1) (5μM-20μM, 14 days) demonstrates no substantial influence on the activity of CT26 cells^[1].
PARP7-IN-22 (49 nM-4000 nM, 72 h) significantly enhances the expression of IFN-β and CXCL10, as well as the phosphorylation of STAT1, in a dose-dependent manner ^[1].
PARP7-IN-22 (49 nM-4000 nM, 72 h) administration exhibites a noticeable increase in TBK1 phosphorylation^[1].
PARP7-IN-22 (49 nM-4000 nM, 72 h) effectively promotes the type I interferon signaling cascade, thereby exerting anti-tumor effects^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

RT-PCR^[1]

Cell Line:

CT26 cells
Concentration:

49 nM-4000 nM
Incubation Time:

72 h
Result:

Resulted in a gradual increase in the mRNA levels of IFN-β and CXCL10 as the dose ranged from 49 nM to 4000 nM.

Western Blot Analysis^[1]

Cell Line:

CT26 cells
Concentration:

49 nM-4000 nM
Incubation Time:

72 h
Result:

Resulted in a dose-dependent increase in the protein levels of STAT1 and TBK1, with STAT1 protein levels showing a dose-dependent increase in the range of 49 nM to 4000 nM.

In Vivo

PARP7-IN-22 (XLY-1) (Male rats, 5 mg/kg, i.v.; 30 mg/kg, p.o; 0.5-24 h) can be administered orally for further in vivo pharmacodynamic studies^[1].
PARP7-IN-22 (CT26 syngeneic model, 25 or 50 mg/kg, p.o., 14 days) demonstrates excellent anti-tumor proliferative effects in the CT26 syngeneic model ^[1].
PARP7-IN-22 (CT26 syngeneic model, 50 mg/kg, p.o., 14 days) promotes T cell infiltration into tumor tissues and exhibits targeted effects^[1].
1.19
Pharmacokinetic Analysis in CT26 Syngeneic Model^[1]

PARP7-IN-22 (XLY-1)	T_1/2(h)	T_max (h)	C_max(g/mL)	C₀(g/mL)	AUC_0-∞(h ng/mL)	V_z(L/kg)	CL (L/h/kg)	MRT_0-∞(h)	F (%)
i.v. (5 mg/kg)	5.42	1.25	353.80	1632.80	1626.00	0.029	0.004	3.22	-
p.o. (30 mg/kg)	5.52	1.75	674.00	-	2368.10	0.112	0.014	4.84	24.27

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 2946705-91-3
Appearance Solid
Molecular Weight 508.42
Formel C₁₉H₂₂F₆N₈O₂
Color White to off-white
SMILES

O=C1NN=CC(NCCCCNC(N2CCN(CC2)C3=NC=C(C(F)(F)F)C=N3)=O)=C1C(F)(F)F
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (196.69 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.9669 mL

9.8344 mL

19.6688 mL

5 mM

0.3934 mL

1.9669 mL

3.9338 mL

10 mM

0.1967 mL

0.9834 mL

1.9669 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (4.92 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (4.92 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (4.92 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (274 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Yang J, et al. Discovery of highly potent PARP7 inhibitors for cancer immunotherapy[J]. Bioorganic Chemistry, 2024, 148: 107469. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.9669 mL	9.8344 mL	19.6688 mL	49.1719 mL
	5 mM	0.3934 mL	1.9669 mL	3.9338 mL	9.8344 mL
	10 mM	0.1967 mL	0.9834 mL	1.9669 mL	4.9172 mL
	15 mM	0.1311 mL	0.6556 mL	1.3113 mL	3.2781 mL
	20 mM	0.0983 mL	0.4917 mL	0.9834 mL	2.4586 mL
	25 mM	0.0787 mL	0.3934 mL	0.7868 mL	1.9669 mL
	30 mM	0.0656 mL	0.3278 mL	0.6556 mL	1.6391 mL
	40 mM	0.0492 mL	0.2459 mL	0.4917 mL	1.2293 mL
	50 mM	0.0393 mL	0.1967 mL	0.3934 mL	0.9834 mL
	60 mM	0.0328 mL	0.1639 mL	0.3278 mL	0.8195 mL
	80 mM	0.0246 mL	0.1229 mL	0.2459 mL	0.6146 mL
	100 mM	0.0197 mL	0.0983 mL	0.1967 mL	0.4917 mL

Keywords

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

PARP7-IN-22

Cell Cycle/DNA Damage Compound Library

Epigenetics Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Orally Active Compound Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Ovarian Cancer Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Alle PARP Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

PARP7-IN-22

Cell Cycle/DNA Damage Compound Library

Epigenetics Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Orally Active Compound Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Ovarian Cancer Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Alle PARP Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

PARP7-IN-22 Related Classifications

HY-163719 Related Classifications